Download full-text PDF |
Source |
---|
PLoS Negl Trop Dis
December 2024
Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Introduction: The World Health Organization (WHO) recommends rifampicin, dapsone and clofazimine multi-drug therapy (MDT) for the treatment of leprosy. Severe adverse effects include dapsone hypersensitivity syndrome, skin pigmentation, haemolytic anaemia, and hepatitis. At the Hospital for Tropical Diseases (HTD), London, United Kingdom monthly rifampicin, ofloxacin and minocycline (mROM) is used as first line treatment for leprosy.
View Article and Find Full Text PDFJ Am Acad Dermatol
December 2024
Department of Dermatology, Stanford University School of Medicine, Redwood City, California. Electronic address:
Background: Hidradenitis suppurativa (HS), a chronic painful inflammatory skin condition, remains a persistent challenge in dermatology. Its complex pathogenesis has yet to be fully understood, complicating the identification of effective therapeutic strategies.
Objective: This study aims to investigate the latest insights on antibiotics, hormonal/metabolic interventions, and oral retinoids in the management of HS.
Sci Rep
November 2024
Department of Microbiology, Immunology and Glycobiology, Institution of Laboratory Medicine, Lund University, Lund, Sweden.
Medicine (Baltimore)
October 2024
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
Rationale: Mycobacterium marinum (M marinum), a slow-growing nontuberculous mycobacterium (NTM), is widely distributed in aquatic environments. It is a well-known cutaneous pathogen, which causes sporotrichosis-like lesions.
Patient Concerns: In this report, we describe 2 cases of subcutaneous M marinum infection.
Pediatr Dermatol
September 2024
Division of Dermatology, Children's National Hospital, Washington, DC, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!